Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England
Authors Paul R Ward, Peter R Noyce, Antony S St Leger
Published 15 April 2005 Volume 2005:1(1) Pages 61—68
Paul R Ward1, Peter R Noyce2, Antony S St Leger3
1School of Health and Related Research, University of Sheffield, England, UK; 2School of Pharmacy and Pharmaceutical Sciences, University of Manchester, England, UK; 3School of Epidemiology and Health Sciences, University of Manchester, England, UK
Aim: To explore the relationship between actual and expected general medical practitioner (GP) practice prescribing rates for statins, angiotensin converting enzyme (ACE) inhibitors, and beta-blockers.
Background: There is a growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The equity of prescribing is of central importance in the area of therapeutics since it explores the interface between those patients who should and those who actually do receive a drug therapy.
Setting: Four primary care trusts (PCTs 1–4) in the North West of England, including 132 GP practices.
Methods: Actual and expected prescribing rates for statins, beta-blockers, and ACE inhibitors were specifically developed for each GP practice.
Results: There were no statistically significant correlations between actual and expected prescribing rates in PCT2 and PCT3, although in PCT1 there were statistically significant correlations for statins (0.286, p < 0.05) and ACE inhibitors (0.381, p < 0.01). In PCT4, correlations were moderate to high for beta-blockers (0.693, p < 0.01), and moderate for statins (0.541, p < 0.05) and ACE inhibitors (0.585, p < 0.01). Scatterplots highlighted large variations between individual GP practices (both within and between PCTs) in terms of the relationship between actual and expected prescribing rates.
Conclusion: This paper highlights variability between PCTs and GP practices in terms of the relationship between actual and expected prescribing rates. The findings from this paper may further advance the suggestion of inequities in prescribing rates for coronary heart disease (CHD) drugs, and studies such as this may be repeated in different therapeutic areas, healthcare settings, and countries.
Keywords: prescribing rates, equity, coronary heart disease, statins, beta-blockers, ACE inhibitor
Readers of this article also read:
Ivanovska-Adjievska B, Boskurt S, Semiz F, Yuzer H, Dimovska-Jordanova V
Published Date: 6 September 2012
Bao-An Chen, Nan Jin, Jun Wang, et al
Published Date: 10 August 2010
Deborah Wolbrette, Mario Gonzalez, Soraya Samii, et al
Published Date: 28 June 2010
Published Date: 23 March 2010
Andrew J Armstrong, Daniel J George
Published Date: 15 November 2007
Swati Jha, Matthew Parsons
Published Date: 15 January 2007
Guido Mannaioni, Roberto Baronti, Flavio Moroni
Published Date: 15 October 2005
Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3
Shenxian Qian, George Somlo, Bingsen Zhou, Yun Yen
Published Date: 15 October 2005
Deanna L McDanel, Barbara A Muller
Published Date: 15 July 2005
Yvonne Koh, Fatimah Bte Moideen Kutty, Shu Chuen Li
Published Date: 15 April 2005